Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes

Abstract

ILC is characterized by lower rates of pathologic response to PC but better long-term outcomes compared to IDC. pCR might not be a prognostic indicator for this group of patients.

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

“…Contrary to other authors, we observed better DDFS and OS for ILC compared to non-ILC [10]. Only pCR patients with ILC had a significantly worse distant disease free survival compared with non-ILC, which might be biased by heterogeneity of baseline factors.…”

“…Using data from 1,051 patients with ILC in this pooled analysis, it was shown that this cohort had a significantly lower pCR rate compared with non-ILC patients. However, biologically aggressive ILCs (HR-and G3) especially in younger patients achieved a pCR rate comparable to nonILCs [8,10,19,20]. Patients with lobular carcinomas were significantly more likely to receive a mastectomy even if a pCR was obtained after neoadjuvant chemotherapy [21][22][23].…”

“…The overall clinical behaviour, however, seems to be better for ILC than for other histological types [10]. There is still controversy as to whether the prognosis of lobular carcinomas differs from ductal invasive carcinomas [5].…”

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

“…It was recently shown that the response to primary chemotherapy is lower in terms of pCR in ILC compared with IDC, with a greater need for mastectomy for the former [21,22]. Conversely, the outcome of ILC appeared to be more favorable than for IDC [20].…”

Comprehensive genetic and functional characterization of IPH‐926: a novel CDH1‐null tumour cell line from human lobular breast cancer

“…ILBCs are mostly oestrogen receptor (ER)-positive and adjuvant endocrine therapy represents the treatment of choice [12]. Several studies have demonstrated the chemoresistance of ILBCs towards conventional anti-cancer agents [12][13][14], perhaps related to the slow proliferation of ILBC cells [13].…”